VALUE OF ASSESSMENT OF DIFFERENT NEOPLASIAS IN THE ADNEXA IN THE DIFFERENTIAL DIAGNOSIS OF MALIGNANT OVARIAN TUMOR AND BENIGN OVARIAN TUMOR: A META-ANALYSIS

To evaluate the accuracy of the assessment of different neoplasias in the adnexa (ADNEX) model in the differential diagnosis of malignant and benign ovarian tumors, the optimal cutoff value and the accuracy in diagnosing ovarian tumors at different stages, PubMed, Web of Science and Cochrane Library databases were retrieved to search literature with per-patient analysis until publication of the last study in November 2021. STATA 14.1, Meta-Disc 1.4 and Revman software 5.3 were used in the performance of meta-analysis. To explore sources of heterogeneity, a subgroup analysis was conducted for the ADNEX model. The pooled sensitivity, specificity, diagnostic odds ratio, positive likelihood, negative likelihood ratio and area under the summary receiver operating characteristic curve were 0.91 (95% confidence interval [CI]: 0.89-0.93), 0.84 (95% CI: 0.80-0.88), 55.55 (95% CI: 40.47-76.26), 5.71 (95% CI: 4.49-7.26), 0.10 (95% CI: 0.08-0.13) and 0.94 (95% CI: 0.92-0.96) in differentiating benign and malignant ovarian tumors, respectively. The area under the curve in identifying benign, borderline, stage I and stages II?IV were 0.93, 0.73, 0.27 and 0.92. The ADNEX model had high diagnostic performance was influential in the diagnosis of benign and stage II-IV ovarian tumors. (E-mail: liuxinjlu01@163.com) (C)& nbsp;2022 World Federation for Ultrasound in Medicine & Biology. All rights reserved.& nbsp;& nbsp;

Automated summary

This study evaluated the accuracy of the ADNEX model in differentiating malignant and benign ovarian tumors and determined the optimal cutoff value for diagnosis. The results showed that the ADNEX model had high sensitivity and specificity in distinguishing between malignant and benign ovarian tumors, and it was particularly effective in diagnosing benign and stage II-IV ovarian tumors.